Zhang Wei, Li Jiping, Yue Liling, Ji Chenfeng
Engineering Research Center for Medicine, College of Pharmacy, Harbin University of Commerce, Harbin 150028, China.
School of Public Health, Qiqihar Medical University, Qiqihar 161006, China.
Pharmaceutics. 2024 Oct 27;16(11):1382. doi: 10.3390/pharmaceutics16111382.
BACKGROUND/OBJECTIVES: Breast cancer, a leading health threat affecting millions worldwide, requires effective therapeutic interventions. Celastrol (CEL), despite its antitumor potential, is limited by poor solubility and stability. This study aimed to enhance CEL's efficacy by encapsulating it within glycyrrhizic acid (GA)-modified lipid calcium carbonate (LCC) nanoparticles for targeted breast cancer therapy.
The 4T1 mouse breast cancer cells were used for the study. GA-LCC-CEL nanoparticles were prepared using a gas diffusion method and a thin-film dispersion method. GA-LCC-CEL were characterized using the zeta-potential, dynamic light scattering and transmission electron microscope (TEM). The in vitro release behavior of nanoparticles was assessed using the in vitro dialysis diffusion method. Cellular uptake was examined using flow cytometry and confocal microscopy. Intracellular ROS and Rhodamine 123 levels were observed under fluorescence microscopy. MTT and colony formation assays assessed cytotoxicity and proliferation, and apoptosis was analyzed by Annexin V-FITC/PI staining. Wound healing and transwell assays evaluated migration, and Western blotting confirmed protein expression changes related to apoptosis and migration.
GA-LCC-CEL nanoparticles displayed a well-defined core-shell structure with a uniform size distribution. They showed enhanced anti-proliferative and pro-apoptotic effects against 4T1 cells and significantly reduced breast cancer cell invasion and migration. Additionally, GA-LCC-CEL modulated epithelial-mesenchymal transition (EMT) protein expression, downregulating Snail and ZEB1, and upregulating E-cadherin.
GA-LCC-CEL nanoparticles represent a promising targeted drug delivery approach for breast cancer, enhancing CEL's antitumor efficacy and potentially inhibiting cancer progression by modulating EMT-related proteins.
背景/目的:乳腺癌是影响全球数百万人的主要健康威胁,需要有效的治疗干预措施。尽管雷公藤红素(CEL)具有抗肿瘤潜力,但其溶解度和稳定性较差,限制了其应用。本研究旨在通过将CEL包裹在甘草酸(GA)修饰的脂质碳酸钙(LCC)纳米颗粒中,用于靶向乳腺癌治疗,以提高CEL的疗效。
使用4T1小鼠乳腺癌细胞进行研究。采用气体扩散法和薄膜分散法制备GA-LCC-CEL纳米颗粒。使用zeta电位、动态光散射和透射电子显微镜(TEM)对GA-LCC-CEL进行表征。采用体外透析扩散法评估纳米颗粒的体外释放行为。使用流式细胞术和共聚焦显微镜检查细胞摄取情况。在荧光显微镜下观察细胞内活性氧(ROS)和罗丹明123水平。MTT和集落形成试验评估细胞毒性和增殖情况,通过Annexin V-FITC/PI染色分析细胞凋亡。伤口愈合试验和Transwell试验评估细胞迁移情况,蛋白质印迹法确认与细胞凋亡和迁移相关的蛋白质表达变化。
GA-LCC-CEL纳米颗粒呈现出明确的核壳结构,尺寸分布均匀。它们对4T1细胞显示出增强的抗增殖和促凋亡作用,并显著降低乳腺癌细胞的侵袭和迁移能力。此外,GA-LCC-CEL调节上皮-间质转化(EMT)蛋白表达,下调Snail和ZEB1,上调E-钙黏蛋白。
GA-LCC-CEL纳米颗粒是一种有前途的乳腺癌靶向给药方法,通过调节与EMT相关的蛋白质,提高了CEL的抗肿瘤疗效,并可能抑制癌症进展。